The introduction of new drugs such as ibrutinib (IBR), idelalisib, and venetoclax has changed the standard treatment of the chronic lymphocytic leukemia (CLL),1-3 but the allogeneic stem cell transplantation (hematopoietic stem cell transplantation, HSCT) remains a gold‐standard for relapse‐refractory fit young patients who progress after Bruton Kinase Inhibitors or anti‐Bcl2.4, 5 HSCT is the only curative treatment, with also chimeric antigen receptor T cell (CAR‐T), that has a potential long‐term disease free survival control, because of still limited follow‐up, in high risk or refractory CLL patients.4 IBR is safe and effective in naive or relapsed/refractory CLL patients also in high risk patients (17p deletion or TP53 mutation).6, 7 While there are many published data describing the use of IBR in frontline or relapsed/refractory patients6; the role and the timing of IBR in relapsed CLL patients, expecially during long term follow‐up, post allogeneic HSCT is still unclear.
|Numero di pagine
|Stato di pubblicazione
|Pubblicato - 2020
- efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogenic hematopoietic stem cell transplantation